Skip to main content

Table 2 Survival analyses of prognostic factors

From: The impact of AMIGO2 on prognosis and hepatic metastasis in gastric cancer patients

  

No. patients

OS

  

DSS

  
   

MST (days)

95% CI

P value

MST (days)

95% CI

P value

Age (years)

 < 70

58

NA

NA

0.164

NA

NA

0.272

 ≥ 70

70

2497

NA

 

NA

NA

 

Sex

male

97

NA

NA

0.315

NA

NA

0.487

female

31

2473

981–3965

 

NA

NA

 

BMI

 < 25

108

NA

NA

0.907

NA

NA

0.491

 ≥ 25

20

NA

NA

 

NA

NA

 

Neoadjuvant chemotherapy

yes

41

849

359–1339

 < 0.001a

875

616–1134

 < 0.001 a

no

87

NA

NA

 

NA

NA

 

Adjuvant chemotherapy

yes

11

1120

716–1524

 < 0.001 a

1285

784–1786

 < 0.001 a

no

117

NA

NA

 

NA

NA

 

Stage (UICC 7th)

I

62

NA

NA

0.001 a

NA

NA

 < 0.001 a

II/III/IV

66

1430

264–2596

 

1811

NA

 

Histlogical type

poor/sig

64

NA

NA

0.199

NA

NA

0.467

well/mod/other

64

2291

NA

 

NA

NA

 

Vascular invasion

negative

47

NA

NA

0.030 a

NA

NA

0.005 a

positive

81

2345

NA

 

NA

NA

 

Lymphatic invasion

negative

41

NA

NA

0.027 a

NA

NA

0.005 a

positive

87

2473

NA

 

NA

NA

 

pT

I/II

72

NA

NA

0.011 a

NA

NA

 < 0.001 a

III/IV

56

1430

682–2178

 

1574

NA

 

pN

0

73

NA

NA

 < 0.001 a

NA

NA

 < 0.001 a

1

55

1187

711–1663

 

1293

512–2074

 

CEA (ng/mL)

 < 5

113

NA

NA

0.664

NA

NA

0.641

 ≥ 5

15

NA

NA

 

NA

NA

 

CA19-9 (U/mL)

 < 35

98

NA

NA

0.895

NA

NA

0.440

 ≥ 35

30

NA

NA

 

NA

NA

 

Liver metastasis

presence

15

664

394–934

 < 0.001 a

664

394–934

 < 0.001 a

absence

113

NA

NA

 

NA

NA

 

Peritoneal dissemination

presence

20

699

305–1093

 < 0.001 a

699

305–1093

 < 0.001 a

absence

108

NA

NA

 

NA

NA

 

AMIGO2

low

99

NA

NA

0.004 a

NA

NA

 < 0.001 a

high

29

977

725–1229

 

1103

0–2587

 
  1. OS overall survival, DSS disease-specific survival, CI confidence interval, MST median survival time, BMI body mass index, sig/poor/mod/well signet-ring cell/poorly/moderately/well differentiated, pT/N pathological T/N stage, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen19-9, NA not applicable, astatistically significant